Figure 3 from Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study

Effects of IL-6 and ANXA1 on alectinib sensitivity. A, WB analysis of ANXA1, LCN2, and CLDN4 in H3122, ABC-14, ABC-17, ABC-19, and ABC-23 cells. Data are representative of three independent experiments with similar results. B, WB analysis of ANXA1, STAT3, and phospho-STAT3 (pSTAT3) in H3122 cells treated with varying concentrations of IL-6 for 24 hours. Data are representative of three independent experiments with similar results. C, Cell proliferation assays at increasing concentrations with or without IL-6 (20 ng/mL) in H3122 cells treated with alectinib for 72 hours. Data are presented as the mean ± standard error (n = 9 per group). *, P < 0.05, Student t test. D, IC50 values of alectinib in H3122 cells with or without IL-6 treatment (20 ng/mL). Data are presented as the mean ± standard error (n = 9 per group). *, P < 0.05, Student t test. E, WB analysis of ANXA1 expression in ABC-14 cells transfected with negative control siRNA or two different siRNAs targeting ANXA1 (siANXA1 #1, #2). Data are representative of three independent experiments with similar results. F, Cell proliferation assays in ABC-14 cells transfected with negative control siRNA (nega_si) or different siRNAs targeting ANXA1 [siANXA1 #1 (si#1), #2 (si#2)] treated with alectinib (Alec; 0.1 μmol/L) for 72 hours. n = 5 per group. Error bars represent the standard error. *, P < 0.05; ***, P < 0.001, Student t test comparing each siANXA1 group (Alec + si#1 or #2) with the negative control group (Alec + nega_si).